INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 4)
Source: Pixabay

INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 4)

Before you read on, make sure to check out: Part 1: Green Bay Packers' Shemar Jean-Charles and Los Angeles Chargers' Storm Norton talk about the importance of Alzheimer's disease awareness. …

Continue Reading INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 4)

Pancreatic Cancer Patients in the Phase 2 OCLURANDOM Trial See a Twelve Month Progression-Free Survival of 80 Percent

Medscape Medical News reports that results have been received from the OCCLURANDOM Phase 2 trial which is the first randomized trial investigating the antitumor effect of the peptide receptor radionuclide…

Continue Reading Pancreatic Cancer Patients in the Phase 2 OCLURANDOM Trial See a Twelve Month Progression-Free Survival of 80 Percent
PRRT and OCLU Improved Progression-Free Survival for Pancreatic Cancer
mohamed_hassan / Pixabay

PRRT and OCLU Improved Progression-Free Survival for Pancreatic Cancer

Are there therapeutic options for patients living with unresectable (inoperable) pancreatic cancer? According to an article in MedScape, researchers sought to understand whether sunitinib or a combination of peptide receptor…

Continue Reading PRRT and OCLU Improved Progression-Free Survival for Pancreatic Cancer
Dallas University Researcher and Colleagues Create a Molecule That Kills a Wide Range of Treatment-Resistant Cancers
source: pixabay.com

Dallas University Researcher and Colleagues Create a Molecule That Kills a Wide Range of Treatment-Resistant Cancers

  Dr. Jung-Mo Ahn, associate professor at Dallas University in Texas, created a molecule that kills a broad range of treatment-resistant cancers. The newly targeted group includes triple-negative breast cancer.…

Continue Reading Dallas University Researcher and Colleagues Create a Molecule That Kills a Wide Range of Treatment-Resistant Cancers
FDA Orphan Drug Designation for AML and Pancreatic Cancer Treatment Possibly More Effective Than Chemotherapy
source: pixabay.com

FDA Orphan Drug Designation for AML and Pancreatic Cancer Treatment Possibly More Effective Than Chemotherapy

The FDA has just provided AB001 the Orphan Drug designation for both acute myeloid leukemia (AML) and pancreatic cancer. This small molecule was developed by Vopec Pharmaceuticals and Agastiya Biotech.…

Continue Reading FDA Orphan Drug Designation for AML and Pancreatic Cancer Treatment Possibly More Effective Than Chemotherapy

The PanCAN PurpleStride Walk in Detroit Demonstrates the Resolve of Pancreatic Cancer Patients

In Detroit, activists recently came together to raise money for pancreatic cancer research through a walk called “The PanCAN PurpleStride walk.” Each year about 62,000 people are newly diagnosed with pancreatic…

Continue Reading The PanCAN PurpleStride Walk in Detroit Demonstrates the Resolve of Pancreatic Cancer Patients

Tokyo University Researchers Develop a Hydrogel to Prevent Complications in Post Operative Pancreatic Surgery

The Tokyo University of Science recently published a report stating that its team of scientists was successful in developing a polymer-based-hydrogel, a welcomed improvement to the complicated formulations currently in…

Continue Reading Tokyo University Researchers Develop a Hydrogel to Prevent Complications in Post Operative Pancreatic Surgery